Melanoma

• An FDA advisory committee has voted in favor of RP1, an experimental melanoma drug developed by Replimune, despite the therapy being rejected in April. • The decision comes during a review meeting where experts evaluated the drug's efficacy and safety for treating melanoma patients. • This endorsement marks a significant reprieve for Replimune, potentially reversing a previous regulatory setback under new FDA leadership.

Underwater expedition by Florida-based team supports possible therapeutic use of bacterial toxins from sea squirtsResearchers at a Florida university say bacterial toxins produced by tiny marine organisms they have studied in Antarctica could become an effective treatment for melanoma, the deadliest form of skin cancer.A team from the University of South Florida (USF) recently returned from a six-week expedition to one of the world’s remotest regions in which they collected samples of ascidians, invertebrates known as sea squirts that thrive in the icy waters. Continue reading...

Cancer Research UK figures show number diagnosed with most serious form of skin cancer has risen above 20,000 for first timeThe number of cases from the most serious form of skin cancer have reached a record high across the UK, according to analysis by a leading cancer charity.Melanoma cases in the UK have risen above 20,000 for the first time ever, with 20,980 people being diagnosed with the form of cancer in 2022, according to analysis of the latest figures by Cancer Research UK. Continue reading...